.jpeg)
How effective is Vericiguat tablets?
Vericiguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of patients with chronic heart failure with reduced ejection fraction (LVEF <45%) to reduce the risk of hospitalization or emergency room treatment due to exacerbation of heart failure. Its efficacy has been verified in multiple clinical trials, especially the results of the "VICTORIA" study, which provide strong evidence support for its application.
1. Evidence of efficacy from the VICTORIA study
The VICTORIA study is an international multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial that enrolled 5,050 patients with chronic heart failure with reduced ejection fraction to evaluate the efficacy of vericiguat. The research results show:
Vericiguat significantly reduced the risk of cardiovascular death or hospitalization for worsening heart failure by 10% compared with placebo (HR=0.90, P=0.02).
Vericiguat reduces the risk of hospitalization for heart failure and significantly reduces the likelihood that patients will need to be readmitted to the hospital due to worsening of their condition.
Reduced heart failure hospitalizations: The use of vericiguat significantly reduced the number of hospitalizations due to worsening heart failure and improved patients' quality of life.
Improve cardiac function: Studies have found that vericiguat can increase cardiac output and reduce cardiac pre- and postload, thereby improving cardiac function.
Good long-term tolerance: Although vericiguat may cause mild hypotension and anemia, it is generally well tolerated and most patients can use it long-term without serious adverse reactions.
3. Comparison of efficacy and clinical significance
Vericiguat is currently the only sGC stimulator approved for patients with chronic heart failure with reduced ejection fraction and may provide additional clinical benefit to high-risk patients when used in combination with standard heart failure treatments. Although the efficacy is not groundbreaking compared to other drugs (such as ARNI), it provides a new treatment option for patients with previous heart failure hospitalizations and helps to improve heart failure management.
Vericiguat has been shown in clinical trials to reduce the risk of heart failure hospitalization and provide additional benefit over standard treatment. Its good tolerance and unique mechanism of action make it one of the effective treatment options for patients with chronic heart failure.
Reference: https://www.gilead.com
1. Evidence of efficacy from the VICTORIA study
The VICTORIA study is an international multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial that enrolled 5,050 patients with chronic heart failure with reduced ejection fraction to evaluate the efficacy of vericiguat. The research results show:
Vericiguat significantly reduced the risk of cardiovascular death or hospitalization for worsening heart failure by 10% compared with placebo (HR=0.90, P=0.02).
Vericiguat reduces the risk of hospitalization for heart failure and significantly reduces the likelihood that patients will need to be readmitted to the hospital due to worsening of their condition.
On the basis of previous standard heart failure treatments (such as beta-blockers, ACEI/ARB/ARNI, etc.), the additional benefits of vericiguat further improve the prognosis of patients.
Reduced heart failure hospitalizations: The use of vericiguat significantly reduced the number of hospitalizations due to worsening heart failure and improved patients' quality of life.
Improve cardiac function: Studies have found that vericiguat can increase cardiac output and reduce cardiac pre- and postload, thereby improving cardiac function.
Good long-term tolerance: Although vericiguat may cause mild hypotension and anemia, it is generally well tolerated and most patients can use it long-term without serious adverse reactions.
3. Comparison of efficacy and clinical significance
Vericiguat is currently the only sGC stimulator approved for patients with chronic heart failure with reduced ejection fraction and may provide additional clinical benefit to high-risk patients when used in combination with standard heart failure treatments. Although the efficacy is not groundbreaking compared to other drugs (such as ARNI), it provides a new treatment option for patients with previous heart failure hospitalizations and helps to improve heart failure management.
Vericiguat has been shown in clinical trials to reduce the risk of heart failure hospitalization and provide additional benefit over standard treatment. Its good tolerance and unique mechanism of action make it one of the effective treatment options for patients with chronic heart failure.
Reference: https://www.gilead.com
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
